Clozapine and the Mandatory Monitoring System
- 14 February 1991
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 324 (7) , 490-491
- https://doi.org/10.1056/nejm199102143240712
Abstract
Dr. Salzman, in his Sounding Board article (Sept. 20 issue),1 has identified key aspects of what he generously characterizes as an "unusual" marketing strategy employed by Sandoz in tying the availability of the new antipsychotic agent clozapine (Clozaril) to its own monitoring and distribution system (the Clozaril Patient Monitoring System, or CPMS). This logistically cumbersome system accounts for some $7,000 of the exorbitant $9,000 annual cost per patient for Clozaril.Keywords
This publication has 7 references indexed in Scilit:
- Mandatory Monitoring for Side EffectsNew England Journal of Medicine, 1990
- Clozapine for psychosis in Parkinson's diseaseMovement Disorders, 1990
- Clozapine‐responsive tremor in Parkinson's diseaseMovement Disorders, 1990
- Clozapine in the treatment of psychosis in Parkinson's diseaseNeurology, 1989
- Clozapine in the treatment of tremorActa Neurologica Scandinavica, 1986
- Treatment of drug-induced exogenous psychosis in Parkinsonism with clozapine and fluperlapineArchiv Fur Psychiatrie Und Nervenkrankheiten, 1985